<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04301557</url>
  </required_header>
  <id_info>
    <org_study_id>B2019-177-01</org_study_id>
    <nct_id>NCT04301557</nct_id>
  </id_info>
  <brief_title>PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer</brief_title>
  <official_title>PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PD1 antibody is now recommended for dMMR/MSI-H metastatic colorectal cancer patients as
      second line. Chemoradiotherapy is standand treatment for locally advanced rectal cancer and
      is also recommended as an alternative choice for unresectable locally advanced colon cancer.
      Thus, this study will investigate the efficacy and toxicity of combination strategy using PD1
      antibody and chemoradiotherapy for dMMR/MSI-H locally advnaced colorectal cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PD1 antibody is recommended for dMMR/MSI-H metastatic colorectal cancer patients as second
      line. Chemoradiotherapy is standand treatment for locally advanced rectal cancer and is also
      recommended as an alternative choice for unresectable locally advanced colon cancer. Thus,
      this phase II, single arm study will investigate the efficacy and toxicity of combination
      strategy using PD1 antibody and chemoradiotherapy for dMMR/MSI-H locally advnaced colorectal
      cancer patients, which is expected to yield higher tumor regressiona with tolerable toxicity.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological Complete Response(pCR)</measure>
    <time_frame>1 week after surgery</time_frame>
    <description>According to pathological response to assess the efficiency of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute toxicities</measure>
    <time_frame>Up to 3 months after adjuvant treatment</time_frame>
    <description>Acute toxicities according to CTCAE5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor regression grade</measure>
    <time_frame>1 week after surgery</time_frame>
    <description>Tumor regression grade</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>1 week after surgery</time_frame>
    <description>R0 resection rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical Complication</measure>
    <time_frame>Surgery scheduled 6-8 weeks after the end of neoadjuvant treatment</time_frame>
    <description>Surgical Complication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local recurrence</measure>
    <time_frame>From date of randomization until the date of local recurrence, assessed up to 10 years</time_frame>
    <description>Local recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis</measure>
    <time_frame>From date of randomization until the date of death of distant metastasis, assessed up to 10 years</time_frame>
    <description>Distant metastasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3 year disease free survival</measure>
    <time_frame>From date of randomization until the date of disease recurrence, assessed up to 3 years</time_frame>
    <description>3 year disease free survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>DMMR Colorectal Cancer</condition>
  <condition>MSI-H Colorectal Cancer</condition>
  <condition>Locally Advanced Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>PD1 Antibody and Chemoradiotherapy for dMMR/MSI-H LACRC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction regimen: Capeox+PD1 antibody for 1 cycle, Concurrent chemoradiotherapy regimen: Capeox+PD1 antibody for 2 cycles and concurrent , Interval regimen: Capeox+PD1 antibody for 1 cycle, TME surgery or watch and wait for cCR patients Adjuvant regimen: Capeox+PD1 antibody for 2 cycles, Capecitabine+PD1 antibody for 2 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-1 Antibody</intervention_name>
    <description>PD-1 antibody 240mg,I.V,D1,repeat every 3 weeks, Four cycles in the neoadjuvant treatment, and four cycles in the adjuvant treatment,</description>
    <arm_group_label>PD1 Antibody and Chemoradiotherapy for dMMR/MSI-H LACRC</arm_group_label>
    <other_name>Toripalimab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Oxiliplatin 130mg/m^2 (100mg/m^2 during radiotherapy),I.V,D1,repeat every 3 weeks, Four cycles in the neoadjuvant treatment in Capeox regimen, and two cycles in the adjuvant treatment in Capeox regimen</description>
    <arm_group_label>PD1 Antibody and Chemoradiotherapy for dMMR/MSI-H LACRC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 1000mg/m^2,Bid,P.O,D1-D14,repeat every 3 weeks, Four cycles in the neoadjuvant treatment in Capeox regimen, and two cycles in the adjuvant treatment in Capeox regimen, and two cycles in adjuvant treatment in Capecitabine regimen</description>
    <arm_group_label>PD1 Antibody and Chemoradiotherapy for dMMR/MSI-H LACRC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>External beam radiotherapy</intervention_name>
    <description>Neoadjuvant radiotherapy, 50Gy/25Fractions to the GTV, 45Gy/25Fractions to the CTV</description>
    <arm_group_label>PD1 Antibody and Chemoradiotherapy for dMMR/MSI-H LACRC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total mesorectal excision</intervention_name>
    <description>Total mesorectal excision</description>
    <arm_group_label>PD1 Antibody and Chemoradiotherapy for dMMR/MSI-H LACRC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically proven diagnosis of colorectal adenocarcinoma;

          2. Biopsy tissues with IHC indicates deficient mismatch repair(dMMR),that is,the loss of
             at least one of the four proteins ,MSH1,MSH2,MSH6,PMS2;or gene detection implies
             MSI-H;

          3. Clinical stage for rectal cancer patients is cT3-4N0M0 or cTxN+M0;clinical stage of
             colon cancer should meet the following criteria (any one is sufficient): a)Tumor
             penetrates the whole wall and adherents to other organs or structures
             around(T4b).Tumor cannot reach R0 resection by imaging assessment; b)The intestinal
             lymph nodes involved are closely adjacent to large abdominal vessels. Lymph nodes
             dissection is not feasible by imaging assessment; c)Surgeons assess it is hard to
             achieve R0 resection after surgical exploration; d)Surgeons assess tumor is extensive
             multiviseral resection is needed, which is expected to damage the organs and seriously
             affect the quality of life after operation;

          4. Preoperative staging methods: all patients need to accept digital rectal
             examination(DRE).Patients with rectal cancer undergo high-resolution MRI±ultrasound
             colonoscopy/transrectal ultrasound for preoperative staging. Perienteric lymph nodes
             with short diameter ≥10mm or the shape of lymph nodes and its MRI characteristics are
             consistent with typical lymph node metastasis. If endoscopic ultrasonography is used
             in combination, and there is a contradiction between staging methods, the data should
             be submitted to the evaluation team of our center for the accurate staging;

          5. No symptoms of ileus; or ileus is alleviated after proximal colostomy.

        Previous treatment:

          1. No surgery except preventative stoma;

          2. No chemotherapy or radiotherapy;

          3. No biotherapy (e.g.monoclonal antibodies), immunotherapy (e.g.anti-PD-1
             antibody,anti-PD-L1 antibody,anti-PD-L2 antibody or CTLA-4 antibody),or other clinical
             trials agents;

          4. No limit to previous endocrine therapy.

        Patient characteristics:

          1. Age between 18 and 72 years;

          2. ECOG performance status of 0 or 1;

          3. Life expectancy: more than 2 years;

          4. Hematopoietic: WBC&gt;3×109/L;PLT&gt;80×109/L; Hb&gt;90g/L;

          5. Hepatic: ALT and AST&lt;2 times upper limit of normal (ULN); bilirubin&lt;1.5 times ULN;

          6. Renal: creatinine &lt;1.5 times ULN or creatinine clearance ≥ 60 mL/min.

        Exclusion Criteria:

        All patients enrolled cannot have any of the following situation:

          1. Arrhythmias require antiarrhythmic therapy (with the exception of β-blockers or
             digoxin), symptomatic coronary artery disease or local myocardial ischemia (myocardial
             infarction within the past 6 months) or congestive heart failure exceeding NYHA II;

          2. Severe hypertension with poor drug control;

          3. A known history of testing positive for HIV or chronic hepatitis B or C (high copy
             virus DNA) at active stage;

          4. Patients with active tuberculosis (TB) are receiving anti-tuberculosis treatment or
             have received anti-tuberculosis treatment within 1 year before screening;

          5. Other active severe clinical infections (NCI-CTC5.0);

          6. Apparent distant metastasis away from the pelvic before surgery;

          7. Cachexia, organ function decompensation;

          8. Previous pelvic or abdominal radiotherapy;

          9. Multiple primary colorectal cancers;

         10. Epilepsy require medical treatment (such as steroid or antiepileptic therapy);

         11. Other malignancy within the past 5 years with the exception of effectively treated
             carcinoma in situ of the cervix or basal cell carcinoma of the skin;

         12. Drug abuse and medical, psychological or social factors that may interfere with
             patients' participation in the study or affect the evaluation of the study;

         13. Patients have any active autoimmune diseases or a history of autoimmune
             diseases(including but not limited to: interstitial pneumonia, uveitis, enteritis,
             hepatitis, hypophysitis, nephritis, hyperthyroidism and decreased thyroid function;
             patients with vitiligo or with complete remission of asthma in childhood and without
             any intervention in adulthood may be included; patients with asthma requiring
             bronchodilators intervention are not included.

         14. Received any anti-infection vaccine (e.g. influenza vaccine, chickenpox vaccine, etc.)
             within 4 weeks before enrollment;

         15. Complications require long-term treatment with immunosuppressive drugs, or requiring
             systemic or local use of immunosuppressive corticosteroids(&gt;10mg/day prednisone or
             other therapeutic hormones);

         16. Known or suspected allergy to the study drugs or to any drugs related to this trial;

         17. Any unstable condition or which endangers the patients' safety and compliance;

         18. Pregnant or breast-feeding women who are fertile without effective contraception;

         19. Refuse to sign the informed consent.

        Exit Criteria:

          1. Patients withdraw the informed consent and ask for quit;

          2. Poor compliance;

          3. Disease progression during treatment;

          4. Serious adverse events or serious adverse reactions (SAE) occurred during the study;

          5. Any delay of treatment for more than two weeks (including two weeks) (referring to the
             delay of all drugs in the medication plan) shall be discussed by the researchers
             whether to quit.

        Cessation Criteria:

        Study suspension refers to the cessation of the whole study before the end of the program.
        The main purpose of this action is to protect the rights and interests of the subjects,
        ensure the quality of the study, and avoid unnecessary economic losses. The whole study
        will be stopped for the following reasons:

          1. Researchers find serious safety issues;

          2. Efficacy is poor that there is no need to continue the study;

          3. Severe mistakes in the scheme design or important deviations in the implementation
             process;

          4. Funds or management problems;

          5. The administrative department decide to cancel the study. A complete suspension of
             research is either temporary or permanent. When discontinued, all study records shall
             be retained for future reference.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>72 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>YuanHong Gao, PhD</last_name>
    <phone>86-20-87343491</phone>
    <email>gaoyh@ssysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>WeiWei Xiao, PhD</last_name>
    <phone>86-20-87343491</phone>
    <email>xiaoww@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>YuanHong Gao, PhD</last_name>
      <phone>86-020-87343491</phone>
      <email>gaoyh@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>WeiWei Xiao, PhD</last_name>
      <phone>86-020-87343491</phone>
      <email>xiaoww@sysucc.org.cn</email>
    </contact_backup>
    <investigator>
      <last_name>YuanHong Gao, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>WeiWei Xiao, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>ZhiFan Zeng, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>QiaoXuan Wang, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>WeiHao Xie, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>SuPing Guo, Bachelor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>XiaoXing Hu, Bachelor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Corrigendum to &quot;Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial&quot;. J Natl Cancer Inst. 2018 Jul 1;110(7):794. doi: 10.1093/jnci/djy096.</citation>
    <PMID>29800481</PMID>
  </reference>
  <reference>
    <citation>Croner RS, Merkel S, Papadopoulos T, Schellerer V, Hohenberger W, Goehl J. Multivisceral resection for colon carcinoma. Dis Colon Rectum. 2009 Aug;52(8):1381-6. doi: 10.1007/DCR.0b013e3181ab580b.</citation>
    <PMID>19617748</PMID>
  </reference>
  <reference>
    <citation>Lehnert T, Methner M, Pollok A, Schaible A, Hinz U, Herfarth C. Multivisceral resection for locally advanced primary colon and rectal cancer: an analysis of prognostic factors in 201 patients. Ann Surg. 2002 Feb;235(2):217-25.</citation>
    <PMID>11807361</PMID>
  </reference>
  <reference>
    <citation>Eldar S, Kemeny MM, Terz JJ. Extended resections for carcinoma of the colon and rectum. Surg Gynecol Obstet. 1985 Oct;161(4):319-22.</citation>
    <PMID>4049200</PMID>
  </reference>
  <reference>
    <citation>Chang H, Yu X, Xiao WW, Wang QX, Zhou WH, Zeng ZF, Ding PR, Li LR, Gao YH. Neoadjuvant chemoradiotherapy followed by surgery in patients with unresectable locally advanced colon cancer: a prospective observational study. Onco Targets Ther. 2018 Jan 17;11:409-418. doi: 10.2147/OTT.S150367. eCollection 2018.</citation>
    <PMID>29398921</PMID>
  </reference>
  <reference>
    <citation>Curley SA, Carlson GW, Shumate CR, Wishnow KI, Ames FC. Extended resection for locally advanced colorectal carcinoma. Am J Surg. 1992 Jun;163(6):553-9.</citation>
    <PMID>1595834</PMID>
  </reference>
  <reference>
    <citation>Xin Yu, WeiWei Xiao, Rong Zhang, LuNing Zhang, Bo Qiu, ZhiFan Zeng, Pei-Rong Ding, Zhi-zhong Pan, Li-ren LI, Yuan-Hong Gao. A pilot study of neoadjuvant chemoradiotherapy for unresectable locally advanced adherent colon cancer: Assessing local tumor response. JCO. 2016; 34（4S）: 727.</citation>
  </reference>
  <reference>
    <citation>Qiu B, Ding PR, Cai L, Xiao WW, Zeng ZF, Chen G, Lu ZH, Li LR, Wu XJ, Mirimanoff RO, Pan ZZ, Xu RH, Gao YH. Outcomes of preoperative chemoradiotherapy followed by surgery in patients with unresectable locally advanced sigmoid colon cancer. Chin J Cancer. 2016 Jul 7;35(1):65. doi: 10.1186/s40880-016-0126-y.</citation>
    <PMID>27389519</PMID>
  </reference>
  <reference>
    <citation>Cukier M, Smith AJ, Milot L, Chu W, Chung H, Fenech D, Herschorn S, Ko Y, Rowsell C, Soliman H, Ung YC, Wong CS. Neoadjuvant chemoradiotherapy and multivisceral resection for primary locally advanced adherent colon cancer: a single institution experience. Eur J Surg Oncol. 2012 Aug;38(8):677-82. doi: 10.1016/j.ejso.2012.05.001. Epub 2012 May 24.</citation>
    <PMID>22632848</PMID>
  </reference>
  <reference>
    <citation>Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC; EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006 Sep 14;355(11):1114-23. Erratum in: N Engl J Med. 2007 Aug 16;357(7):728.</citation>
    <PMID>16971718</PMID>
  </reference>
  <reference>
    <citation>Lemery S, Keegan P, Pazdur R. First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication. N Engl J Med. 2017 Oct 12;377(15):1409-1412. doi: 10.1056/NEJMp1709968.</citation>
    <PMID>29020592</PMID>
  </reference>
  <reference>
    <citation>Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.</citation>
    <PMID>26028255</PMID>
  </reference>
  <reference>
    <citation>Diaz LA Jr, Le DT. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015 Nov 12;373(20):1979. doi: 10.1056/NEJMc1510353.</citation>
    <PMID>26559582</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2020</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yuan-hong Gao</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>DMMR Colorectal Cancer</keyword>
  <keyword>MSI-H Colorectal Cancer</keyword>
  <keyword>Locally Advanced Colorectal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

